首页> Genes, chromosomes & cancer> Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.

Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.

导出 OA

翻译打印收藏纠错

第一作者： Darmood,Wei

第一单位： Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.

作者： Darmood,Wei ^[1] ; Youfeng,Yang ^[1] ; Christopher J,Ricketts ^[1] ; Cathy D,Vocke ^[1] ; Mark W,Ball ^[1] ; Carole,Sourbier ^[1] ; Darawalee,Wangsa ^[2] ; Danny,Wangsa ^[2] ; Rajarshi,Guha ^[3] ; Xiaohu,Zhang ^[3] ; Kelli,Wilson ^[3] ; Lu,Chen ^[3] ; Paul S,Meltzer ^[2] ; Thomas,Ried ^[2] ; Craig J,Thomas ^[3] ; Maria J,Merino ^[4] ; W Marston,Linehan ^[1]

作者单位： Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States. ^[1] Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States. ^[2] Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States. ^[3] Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States. ^[4]

关键词 Bortezomib EZH2 inhibitor INI1 RMC SMARCB1 SWI/SNF complex UOK353 UOK360 renal medullary carcinoma